Nascent Biotech files IND for lead product candidate pritumumab; shares up 35%

|About: Nascent Biotech Inc. (NBIO)|By:, SA News Editor

Nascent Biotech (OTCPK:NBIO +34.6%) files its Investigational New Drug (IND) application with the FDA for pritumumab, a fully human monoclonal IgG antibody for the potential treatment of brain tumors and other cancers. Clinical trials should commence in the coming months.